These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21640778)

  • 1. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.
    Velasquez LS; Shira S; Berta AN; Kilbourne J; Medi BM; Tizard I; Ni Y; Arntzen CJ; Herbst-Kralovetz MM
    Vaccine; 2011 Jul; 29(32):5221-31. PubMed ID: 21640778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation.
    Springer MJ; Ni Y; Finger-Baker I; Ball JP; Hahn J; DiMarco AV; Kobs D; Horne B; Talton JD; Cobb RR
    Vaccine; 2016 Mar; 34(12):1452-8. PubMed ID: 26873053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.
    Hjelm BE; Kilbourne J; Herbst-Kralovetz MM
    Hum Vaccin Immunother; 2014; 10(2):410-6. PubMed ID: 24280723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.
    Ball JP; Springer MJ; Ni Y; Finger-Baker I; Martinez J; Hahn J; Suber JF; DiMarco AV; Talton JD; Cobb RR
    PLoS One; 2017; 12(5):e0177310. PubMed ID: 28545100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
    Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
    Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.
    Velasquez LS; Hjelm BE; Arntzen CJ; Herbst-Kralovetz MM
    Clin Vaccine Immunol; 2010 Dec; 17(12):1850-8. PubMed ID: 20962211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
    Garmise RJ; Staats HF; Hickey AJ
    AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.
    Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ
    Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.
    Periwal SB; Kourie KR; Ramachandaran N; Blakeney SJ; DeBruin S; Zhu D; Zamb TJ; Smith L; Udem S; Eldridge JH; Shroff KE; Reilly PA
    Vaccine; 2003 Jan; 21(5-6):376-85. PubMed ID: 12531635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norovirus GII.17 Virus-Like Particles Bind to Different Histo-Blood Group Antigens and Cross-React with Genogroup II-Specific Mouse Sera.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Viral Immunol; 2018 Dec; 31(10):649-657. PubMed ID: 30431404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.
    Atmar RL; Baehner F; Cramer JP; Song E; Borkowski A; Mendelman PM;
    J Infect Dis; 2016 Sep; 214(6):845-53. PubMed ID: 27354368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
    Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
    Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
    Malm M; Heinimäki S; Vesikari T; Blazevic V
    Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination.
    Atmar RL; Baehner F; Cramer JP; Lloyd E; Sherwood J; Borkowski A; Mendelman PM;
    J Infect Dis; 2019 Jul; 220(4):603-614. PubMed ID: 31001633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
    Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.
    Thakkar SG; Warnken ZN; Alzhrani RF; Valdes SA; Aldayel AM; Xu H; Williams RO; Cui Z
    J Control Release; 2018 Dec; 292():111-118. PubMed ID: 30339906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Focusing Properties of Virus-like Particles Improve Protective IgA Responses.
    Onodera T; Hashi K; Shukla RK; Miki M; Takai-Todaka R; Fujimoto A; Kuraoka M; Miyoshi T; Kobayashi K; Hasegawa H; Ato M; Kelsoe G; Katayama K; Takahashi Y
    J Immunol; 2019 Dec; 203(12):3282-3292. PubMed ID: 31704880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.